Metabolic Solutions Development Company to Present Research Findings at Annual American Diabetes Association Conference
KALAMAZOO, Mich., June 15 /PRNewswire/ -- Metabolic Solutions
Development Company (MSDC) will present its research providing
insights into the mechanisms and novel activities of its drug
portfolio at the American Diabetes Association's (ADA) 70th annual
Scientific Sessions conference in Orlando, Fla., which is being
held on June 25-29, 2010. The ADA conference is widely considered
to be the world's leading scientific and medical meeting focused on
diabetes.
MSDC Chief Scientific Officer Jerry Colca, Ph.D., will present
"Evaluation of a PPAR-sparing Thiazolidinedione for Treatment of
Insulin Resistance in Diet-Induced Obese Mice" on June 26 at 2:15
p.m. ET in room 314. The presentation is based on MSDC's
collaborative research with Dr. Brian Finck of Washington
University in St. Louis. The research findings showcase the
compelling pre-clinical activity of MSDC's second drug candidate
(MSDC-0602) in reversing non-alcoholic fatty liver and normalizing
other metabolic parameters, including blood glucose and insulin
response.
MSDC, www.msdrx.com, is developing pharmaceuticals designed to
treat type 2 diabetes more effectively and without the side effects
of current therapies. Phase 2a clinical data from the company's
lead candidate, MSDC-0160, demonstrate that it improves insulin
sensitivity and lowers blood glucose levels in humans without the
side effects of the current market leading diabetes medicines. The
compound also demonstrated significant improvements in other
important metabolic disease parameters, including blood pressure
and lipids.
"The discussion around Avandia has proven that the marketplace
wants diabetes drugs that do more than simply lower blood glucose,"
said Colca. "We've built MSDC around answering that need. The data
that we are presenting, combined with MSDC clinical data, support
that our drug candidates can treat the whole diabetic condition,
including reducing heart attacks and strokes."
Colca's presentation, along with two others by MSDC at this
year's ADA conference, will explain aspects of MSDC's novel target
and the pathways through which the company's clinical candidates
are acting. The presentations also will provide some insights into
insulin re-sensitization and other metabolic benefits with the
company's candidates. These insights may pave the way for a change
in how diabetes is treated.
The other MSDC presentations are:
-- "Activating AMPK and Decreasing mTOR Activation by TZD Treatment
Prevents Insulin Resistance in Human Islet" on June 26 at 11:30 a.m.
ET. This presentation features information describing the activity of
MSDC's initial drug candidate (MSDC-0160) in improving human
pancreatic islet cell function. The information is based on
collaborative research with Dr. Michael McDaniel of Washington
University in St. Louis.
-- "Induction of Brown Adipose Cell Differentiation by PPAR-sparing
Thiazolidinedoines" on June 27 at noon ET. This presentation features
information describing the mechanism through which MSDC's candidates
promote proliferation of brown fat, which is a rapidly emerging area
of research in metabolic disease. Research shows that the presence of
brown fat in the body may help control body weight. An increase in
brown fat may make PPAR-sparing insulin sensitizers especially useful
in the treatment of diabetes as current treatments often result in
weight gain.
About Metabolic Solutions Development Company:
Metabolic Solutions Development Company (www.msdrx.com), based
in Kalamazoo, Mich., is developing innovative therapeutics using a
different pharmacological path to treat type 2 diabetes and related
metabolic diseases. This new approach seeks to improve the efficacy
of treatment and free patients from the adverse side effects of
current treatments, including edema and weight gain.
The company's program and candidates are built on its leaders'
extensive experience with insulin sensitizers and a unique insight
into the mechanism of insulin-sensitizing pharmacology. The company
has identified a novel (non-PPAR) target that delivers the superior
efficacy of insulin sensitizers without the side effects of current
sensitizers, and believes that the result will be a new generation
of superior, safer drug therapies.
CONTACT: Nick Wasmiller SeyferthPR 1-800-435-9539 wasmiller@seyferthpr.com
Source: Metabolic Solutions Development Company
CONTACT: Nick Wasmiller, SeyferthPR, 1-800-435-9539,
wasmiller@seyferthpr.com
Web Site: http://www.msdrx.com/
Posted: June 2010
